{
  "id": 20948521,
  "title": "Ionis Pharmaceuticals stock hits 52-week low at 26.54 USD",
  "url": "https://urgent.news/2026/11/20/ionis-pharmaceuticals-stock-hits-52-week-low-at-26-54-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T20:57:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/ionis-pharmaceuticals-stock-hits-52week-low-at-2654-usd-93CH-5042587"
  },
  "original_language": "en",
  "account": "Ionis Pharmaceuticals Inc. stock has fallen to a 52-week low of $26.54, trading at $26.56 just above that low. The company's shares have declined by 64.82% over the past year, reflecting ongoing challenges in the pharmaceutical sector. The stock's Relative Strength Index (RSI) indicates it is in oversold territory, signaling potential buying opportunities. Analysts rate Ionis with a consensus buy rating, with price targets ranging from $41 to $105. However, InvestingPro data suggests the stock may currently be overvalued. Recent analyst adjustments to price targets follow Ionis' third-quarter financial results, where the company missed revenue estimates for its drug Tryngolza. Guggenheim lowered its target to $65, TD Cowen to $53, and RBC Capital to $60, citing slower-than-expected performance for Tryngolza. Wells Fargo and BofA Securities also reduced their price targets, citing a slower launch and revised guidance for Tryngolza. Despite these challenges, other Ionis products like Dawnzera and Spinraza have performed well, with Wells Fargo noting potential growth as sales clarity improves in 2027.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}